Pfizer's Crizotinib Eases Past FDA With Targeted Population
This article was originally published in The Pink Sheet Daily
Executive Summary
Xalkori is the second targeted oncologic approved with a companion diagnostic this year, FDA says, following Roche's Zelboraf just 10 days prior.
You may also be interested in...
Novartis’ Zykadia Sets New “Breakthrough” Speed Record For NME Review
FDA grants accelerated approval to ceritinib following a four-month review. The ALK inhibitor is indicated for non-small cell lung cancer patients who have progressed on or are intolerant of Pfizer’s Xalkori.
Precision Medicine Will Be In Action At ASCO
Though the tracks and sessions are still named largely for organs and other phenotypic descriptions of cancer, the notion of basing treatments on the molecular drivers of a tumor alone is pervasive at this year’s meeting of the American Society of Clinical Oncology, June 1-5 in Chicago.
Vertex's Cystic Fibrosis Drug Kalydeco Could See Speedy Review
High unmet medical need, a genetically targeted patient population and the drug's biological rationale could combine for a faster-than-six-month approval for the novel, disease-modifying therapy.